electroCore (NASDAQ:ECOR) Announces Quarterly Earnings Results

electroCore (NASDAQ:ECOR) announced its earnings results on Thursday. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.09, FiscalAI reports. electroCore had a negative return on equity of 1,956.38% and a negative net margin of 39.96%.The company had revenue of $9.45 million during the quarter, compared to the consensus estimate of $9.49 million.

Here are the key takeaways from electroCore’s conference call:

• Revenue grew 28% year over year to $9.5 million, driven by VA prescription sales of gammaCore and Quell, along with Truvaga growth. Management raised 2026 revenue guidance to more than 30% growth.
• Operating performance improved, with GAAP net loss narrowing to $3.1 million and adjusted EBITDA loss improving 26% year over year to $1.8 million. Management believes the commercial restructuring creates a path to positive adjusted EBITDA in the third quarter of 2027 without a dilutive equity raise.
• Quell was a major growth driver, with second-quarter sales up approximately 700% year over year to $1.3 million. The company is expanding Quell utilization across existing VA accounts and is targeting an FDA submission by year-end for chemotherapy-induced peripheral neuropathy.
• electroCore doubled its sales regions, added 17 independent representatives covering 29 VA medical centers, and is expanding into the Department of Defense, federal workers’ compensation, first responders, and other federal channels. Moving federal supply schedule sales to Lovell Government Services is expected to reduce related costs by roughly 3% of general and administrative expenses and transaction fees.
• Truvaga faced rising competition and advertising costs, with direct cost per click increasing roughly 30% and media efficiency declining. In addition, FDA observations regarding patient-complaint processes will delay a potential Quell 2.0 rebrand and direct-to-consumer relaunch, while VA account concentration remains a risk after a facility staffing issue shifted approximately $145,000 of revenue into the third quarter.

electroCore Stock Up 20.7%

ECOR stock traded up $1.39 during trading on Friday, hitting $8.09. The company had a trading volume of 213,989 shares, compared to its average volume of 67,392. The company has a 50 day simple moving average of $7.69 and a 200-day simple moving average of $6.99. The firm has a market capitalization of $72.97 million, a P/E ratio of -4.87 and a beta of 0.92. electroCore has a 52-week low of $4.16 and a 52-week high of $10.49.

Insiders Place Their Bets

In other electroCore news, CFO Joshua S. Lev sold 6,667 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $9.00, for a total value of $60,003.00. Following the completion of the transaction, the chief financial officer owned 84,889 shares of the company’s stock, valued at approximately $764,001. This trade represents a 7.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Thomas J. Errico acquired 9,992 shares of the firm’s stock in a transaction on Thursday, May 21st. The shares were acquired at an average price of $5.99 per share, with a total value of $59,852.08. Following the completion of the purchase, the director owned 360,071 shares in the company, valued at approximately $2,156,825.29. This trade represents a 2.85% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 7.80% of the company’s stock.

Hedge Funds Weigh In On electroCore

A number of large investors have recently bought and sold shares of ECOR. Two Sigma Investments LP increased its stake in electroCore by 20.8% during the 3rd quarter. Two Sigma Investments LP now owns 24,603 shares of the company’s stock worth $122,000 after buying an additional 4,231 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of electroCore in the first quarter worth approximately $153,000. Jane Street Group LLC boosted its stake in shares of electroCore by 114.4% in the first quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock worth $246,000 after acquiring an additional 19,599 shares during the last quarter. DRW Securities LLC acquired a new position in electroCore in the 4th quarter valued at $264,000. Finally, NewEdge Advisors LLC raised its stake in electroCore by 857.9% in the 1st quarter. NewEdge Advisors LLC now owns 161,955 shares of the company’s stock valued at $1,083,000 after purchasing an additional 145,047 shares during the last quarter. Institutional investors and hedge funds own 26.74% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of electroCore in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $18.00.

electroCore Company Profile

electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.

The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.